Erika Lisabeth, PhD
she/her/hers
Assistant Professor (Fixed-Term) and Director, ADDRC
Pharmacology & Toxicology
Assistant Professor (Fixed-Term) and Director, ADDRC
Pharmacology & Toxicology
Research
Colleges
Associations
- MSU Drug Discovery
Facilities
- Assay Development and Drug Repurposing Core
Sections
- PHM 801 Fundamental Principles of Pharmacology and Toxicology (in-person) - Fall
- PHM 803 Chemical Disposition in Mammals (in-person) - Fall
- PHM 805 Receptor Pharmacology (in-person) - Fall
Education
- BS, Chemistry, Michigan State University (1999—2023)
- Post-doctoral Training, Cancer Biology, Sanford Burnham Prebys Medical Discovery Institute (2009—2013)
- PhD, Chemistry and Biochemistry , University of California, San Diego (2003—2009)
Funding
- Development of cellular HTS for 20S proteasome enhancers, National Institute of Neurological Disorders and Stroke (2019-12-01—2022-11-30)
- Development of Cellular HTS for 20S Proteasome Enhancers, National Institute of Neurological Disorders and Stroke (2019-12-01—2024-03-31)
- Mapping the EphA Receptor Landscape in Lung Cancer, Tobacco-Related Disease Research Program (University of California) (2011-09-01—2014-08-31)
Works
- Mass Spectrometry, Structural Analysis, and Anti-Inflammatory Properties of Photo-Cross-Linked Human Albumin Hydrogels. ACS Applied Bio Materials (2022)
- Transforming growth factor β1 increases expression of contractile genes in human pulmonary arterial smooth muscle cells by potentiating sphingosine-1-phosphate signaling. Molecular Pharmacology (2021)
- Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells. Oncogene (2020)
- 5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. Journal of Medicinal Chemistry (2019)
- Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds. ACS Pharmacology and Translational Science (2019)
- The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in Kras G12D ; Pdx1-Cre (KC) mice. Scientific Reports (2019)
- Identification of Pirin as a Molecular Target of the CCG-1423/CCG- 203971 Series of Anti-Fibrotic and Anti-Metastatic Compounds. bioRxiv (2018)
- Rho-mediated gene transcription promotes BRAF inhibitor resistance in de-differentiated melanoma cells. bioRxiv (2018)
- Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis. Scientific Reports (2017)
- Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorganic and Medicinal Chemistry Letters (2017)
- Pharmacological inhibition of myocardin-related transcription factor pathway blocks lung metastases of RhoC-Overexpressing melanoma. Molecular Cancer Therapeutics (2017)
- Attenuation of Eph receptor kinase activation in cancer cells by coexpressed ephrin ligands. PLoS ONE (2013)
- Eph receptor signaling and ephrins. Cold Spring Harbor Perspectives in Biology (2013)
- Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. Biochemistry (2012)
- Flexible regions within IκBα create the ubiquitin-independent degradation signal. Journal of Biological Chemistry (2010)
- NF-κB dictates the degradation pathway of IκBα. EMBO Journal (2008)
- NF-κB dictates the degradation pathway of IκBα (EMBO Journal (2008) DOI: 10.1038/emboj.2008.73). EMBO Journal (2008)
- Pre-folding IκBα Alters Control of NF-κB Signaling. Journal of Molecular Biology (2008)
- The Structure of Apo-wild-type Cellular Retinoic Acid Binding Protein II at 1.4 Å and its Relationship to Ligand Binding and Nuclear Translocation. Journal of Molecular Biology (2006)
Employment
- Assistant Professor, Michigan State University (2014-06-01)